Market Overview:
The global shingles vaccine market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of shingles, rising awareness about shingles and its prevention, and the launch of new and innovative vaccines. The global shingles vaccine market is segmented on the basis of type, application, and region. On the basis of type, it is divided into two segments: Zostavax and Shingrix. The Zostavax segment accounted for a major share of the global shingles vaccine market in 2017 owing to its high demand among adults aged 50 years or older. However, with the launch of Shingrix – a more efficacious vaccine – in late 2017 by GlaxoSmithKline (GSK), this segment is expected to witness significant growth during the forecast period. On the basis of application, it is classified into four segments: under 50 years old, 50-60 years old, 60-70 years old, and above 70 years old.
Product Definition:
Shingles vaccine is a vaccine used to prevent shingles, an infection caused by the herpes zoster virus. It is a live attenuated vaccine, meaning it contains a weakened form of the virus. The vaccine is recommended for adults over 60 years old, as well as for adults who have risk factors for developing shingles, such as having cancer or HIV/AIDS.
Zostavax:
Zostavax (Zoster Vaccine Live) is a vaccine for the prevention of shingles. It was approved by the FDA in 2006 and has been recommended to almost all adults over 60 years of age, as well as people with weak immune systems including those with AIDS or cancer. The Centers for Disease Control and Prevention (CDC) recommends that everyone over 50 years of age should get vaccinated, however; there is no evidence regarding its benefits in younger individuals.
Shingrix:
Shingrix is a new shingles vaccine that was approved by the FDA in 2018. It is the only one that works against both Zostavax (ZDV) and Shingrix. The approval of this vaccine will help to reduce the number of people who get shingles, which usually leads to hospitalization every year in U.S., especially among older adults and those with weak immune systems.
Application Insights:
The application segment is sub-divided into under 50 years old, 50-60 years old, 60-70 years old and above 70 years olds. The U.S., Germany, Russia and France are estimated to account for the largest share of the population above 70 in each country which will increase the demand for shingles vaccine during the forecast period.
Based on age groupings, vaccines are targeted towards people below 60 as well as those who have reached or exceeded 60 years of age; however; due to various factors such as lack of awareness about vaccination benefits among older population groups in developing countries like China and India; only a portion of older population is covered by these vaccines thus creating a huge potential market that can be exploited during this forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a strong healthcare infrastructure and high awareness regarding shingles vaccination are some of the major factors responsible for its large share. In addition, government initiatives to raise funds for vaccine development also help boost revenue generation in this region. For instance, Shingrix is being funded by an NIH grant (U01 AI068011) along with other private donations and investments from Merck & Co., Inc.
Asia Pacific is expected to be the fastest-growing regional market during the forecast period owing to increasing geriatric population base coupled with rising disposable income levels in emerging economies such as China and India.
Growth Factors:
- Increasing incidence of shingles across the globe
- Growing awareness about shingles and its prevention among people
- Rising demand for shingles vaccine due to increasing number of elderly population
- Technological advancements in the field of vaccine development
- Government initiatives and programs to promote vaccination against shingles
Scope Of The Report
Report Attributes
Report Details
Report Title
Shingles Vaccine Market Research Report
By Type
Zostavax, Shingrix
By Application
Under 50 Years Old, 50-60 Years Old, 60-70 Years Old, Above 70 Years Old
By Companies
Merck, GlaxoSmithKline, Merck
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
169
Number of Tables & Figures
119
Customization Available
Yes, the report can be customized as per your need.
Global Shingles Vaccine Market Report Segments:
The global Shingles Vaccine market is segmented on the basis of:
Types
Zostavax, Shingrix
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Under 50 Years Old, 50-60 Years Old, 60-70 Years Old, Above 70 Years Old
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- GlaxoSmithKline
- Merck
Highlights of The Shingles Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Zostavax
- Shingrix
- By Application:
- Under 50 Years Old
- 50-60 Years Old
- 60-70 Years Old
- Above 70 Years Old
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Shingles Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Shingles vaccine is a vaccine that helps protect people from shingles. Shingles is a painful rash that can occur after exposure to the varicella zoster virus (VZV). The vaccine helps prevent shingles by helping your body build immunity to VZV.
Some of the key players operating in the shingles vaccine market are Merck, GlaxoSmithKline, Merck.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Shingles Vaccine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Shingles Vaccine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Shingles Vaccine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Shingles Vaccine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Shingles Vaccine Market Size & Forecast, 2020-2028
4.5.1 Shingles Vaccine Market Size and Y-o-Y Growth
4.5.2 Shingles Vaccine Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Zostavax
5.2.2 Shingrix
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Under 50 Years Old
6.2.2 50-60 Years Old
6.2.3 60-70 Years Old
6.2.4 Above 70 Years Old
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Shingles Vaccine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Shingles Vaccine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Zostavax
9.6.2 Shingrix
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Under 50 Years Old
9.10.2 50-60 Years Old
9.10.3 60-70 Years Old
9.10.4 Above 70 Years Old
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Zostavax
10.6.2 Shingrix
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Under 50 Years Old
10.10.2 50-60 Years Old
10.10.3 60-70 Years Old
10.10.4 Above 70 Years Old
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Zostavax
11.6.2 Shingrix
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Under 50 Years Old
11.10.2 50-60 Years Old
11.10.3 60-70 Years Old
11.10.4 Above 70 Years Old
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Zostavax
12.6.2 Shingrix
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Under 50 Years Old
12.10.2 50-60 Years Old
12.10.3 60-70 Years Old
12.10.4 Above 70 Years Old
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Zostavax
13.6.2 Shingrix
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Under 50 Years Old
13.10.2 50-60 Years Old
13.10.3 60-70 Years Old
13.10.4 Above 70 Years Old
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Shingles Vaccine Market: Competitive Dashboard
14.2 Global Shingles Vaccine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 GlaxoSmithKline
14.3.3 Merck
